% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Hemminki:181669,
      author       = {J. Hemminki and A. Försti$^*$ and A. Hemminki and K.
                      Hemminki$^*$},
      title        = {{S}urvival trends in solid cancers in the {N}ordic
                      countries through 50 years.},
      journal      = {European journal of cancer},
      volume       = {175},
      issn         = {0014-2964},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2022-02153},
      pages        = {77 - 85},
      year         = {2022},
      note         = {#LA:C020#},
      abstract     = {Global survival studies in cancer have generally shown
                      favourable development, but studies over extended periods on
                      populations for which medical care is essentially free of
                      charge are lacking.We analyse relative 1- and 5-year
                      survival in all solid cancers in Denmark, Finland, Norway
                      and Sweden through a 50-year period (1970-2019) using the
                      NORDCAN database.The most recent survival results showed
                      three types of patterns. Cancers of very good survival
                      (5-year survival $∼90\%)$ included common cancers of the
                      breast and prostate, as well as melanoma. The second
                      pattern, which included the largest number of cancers,
                      showed 1-year survival of over $80\%$ and a drop of 10-20
                      $\%$ units in 5-year survival. The third group consisted of
                      eight fatal cancers, sharing poor 5-year survival (around
                      $20\%).$ The 50-year improvement in 1-year survival was
                      largest (30-50 $\%$ units) in kidney, brain, gallbladder and
                      liver cancers, and $(∼30\%)$ in colon, small intestinal,
                      lung, pleural, pancreas and ovarian cancers. Improvements in
                      5-year survival were highest (40-50 $\%$ units) in prostate
                      and kidney cancers but remained at 10-20 $\%$ units for the
                      eight fatal cancers. Survival showed significant sex
                      preferences for a few cancers.The analysis over a
                      half-century confirms the progress in 'real-world' cancer
                      control, and in $84\%$ of patients 5-year survival was
                      $>60\%.$ Metastases remain a challenge, placing the emphasis
                      on early detection before metastasis occurs. Novel
                      therapies, such as immunotherapy which has curative
                      potential even against metastatic disease, are needed.},
      keywords     = {Cancer control (Other) / Periodic survival (Other) /
                      Prognosis (Other) / Treatment (Other)},
      cin          = {B062 / HD01 / C020},
      ddc          = {610},
      cid          = {I:(DE-He78)B062-20160331 / I:(DE-He78)HD01-20160331 /
                      I:(DE-He78)C020-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36096040},
      doi          = {10.1016/j.ejca.2022.08.015},
      url          = {https://inrepo02.dkfz.de/record/181669},
}